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Objective To assess the effects of tibolone on climacteric symptoms, endometrium and serum lipid/ lipoproteins 
in postmenopausal women receiving tamoxifen after surgery for breast cancer. 
Design Double-blind, randomised, placebo-controlled, multicentre pilot study. 
Setting Hospital outpatient clinic. 
Sample Seventy postmenopausal women receiving tamoxifen following surgery for early breast cancer. 
Methods Women received 20 mg/day oral tamoxifen plus either 2.5 mg/day oral tibolone or placebo for 12 
months. 
Main outcome measures Frequency and severity of hot flushes (diary cards); intensity of hot flushes and sweats 
(Landgren scale); interference of hot flushes and sweats with normal life; frequency and intensity of other 
climacteric symptoms; endometrial thickness and histology; vaginal bleeding; breast cancer recurrence and 
serum lipid/lipoproteins. 
Results Daily card data showed no change in the daily number of hot flushes with either tibolone or placebo  
(P = 0.219) after three months. There was a significant reduction in the severity of flushes with tibolone 
compared with placebo (-0.4 vs 0.2, P = 0.031). The Landgren scale showed a mean change in the number of hot 
flushes of -0.6 with tibolone and +1.1 with placebo after 12 months (P = 0.022). Endometrial biopsies were 
normal and vaginal bleeding was similar in both groups. A significant decrease in triglycerides (-23% vs 1.4%) 
and HDL (-12% vs 19%) was seen with tibolone compared with placebo after 12 months. 
Conclusions Tibolone prevented an increase in hot flushes in postmenopausal women given tamoxifen 
following surgery for breast cancer without untoward effects on the endometrium. Beneficial effects on serum 
lipid profile were noted. 
 
INTRODUCTION 
Breast cancer is the most common cancer among women in Western countries. Approximately two-thirds of 
cases occur in postmenopausal women, and hence, many will suffer from climacteric symptoms. Moreover, the 
majority will be given adjuvant tamoxifen that may exacerbate these symptoms and lead to discontinuation of 
adjuvant therapy.1 Combined oestrogen and progestogen therapy has conventionally been contraindicated in 
these women due to fears that oestrogen might stimulate the growth of residual micro-metastases leading to 
recurrence of breast cancer. Although there is no clear evidence of such an effect, the issue of breast cancer and 
oestrogen and progestogen therapy remains highly controversial. Some studies have suggested a reduced 
incidence of recurrence and mortality in breast cancer survivors given oestrogen and progestogen therapy,3 but 
the prematurely stopped HABITS and Stockholm trials did not resolve the debate. 
Tibolone is a drug that has beneficial effects on climacteric symptoms, bone, the vagina, and mood and sexual 
wellbeing5 due to the effects of its two oestrogenic metabolites and a third metabolite with androgenic 
properties.6 This third metabolite also exerts local progestogenic effects in the endometrium and prevents 
endometrial stimulation.7 Tamoxifen acts as an oestrogen agonist on endometrial cells,8 and causes endometrial 
stimulation which may lead to endometrial hyperplasia or cancer.9
Tibolone and its metabolites have a tissue-selective effect in the breast, inhibiting sulphatase activity to prevent 
formation of active oestrogens and stimulating sulpho-transferase to encourage formation of inactive sulphated 
oestrogens. Tibolone stimulates apoptosis and reduces proliferation rate in normal human breast tissues in vitro 
and in vivo.11 Animal studies have shown that it does not stimulate mammary tissue12 and displays an anti-
tumour effect on the breast similar to that of tamoxifen.13
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These findings suggest that tibolone might be beneficial in reducing climacteric symptoms while preventing 
endometrial stimulation associated with tamoxifen. A double-blind, placebo-controlled study was therefore 
conducted to assess whether tibolone could prevent, relieve or delay the occurrence of climacteric symptoms in 
postmenopausal women treated with tamoxifen following breast cancer surgery. 
METHODS 
Postmenopausal women (hospital outpatients; <75 years old; body mass index 18-30 kg/m) with newly 
diagnosed and histologically confirmed invasive or non-invasive early stage breast cancer (<stage IIb), for which 
they were to receive surgical treatment (conservation therapy or modified radical mastectomy) followed by 
tamoxifen, were enrolled in the study. The women were required to have had their last natural menstrual period 
>1 year before diagnosis of breast cancer and to have a serum oestradiol concentration of <30 pg/mL. Exclusion 
criteria included other malignancies, prior hysterectomy and/or bilateral oophorectomy, endometrial 
hyperplasia/adenocarcinoma, cervical smear result showing moderate dysplasia or worse, cardiovascular, 
cerebrovascular or thromboembolic disorders, uterine bleeding of unknown cause, severe liver disorders, drug or 
alcohol abuse in the previous 12 months, requirement for cancer therapy (apart from tamoxifen or radiotherapy) 
or medication that might affect the metabolism of tibolone, and the use of steroids or tamoxifen in the six weeks 
prior to the study or hormonal implants at any time. All women provided written informed consent. The protocol 
was approved by the Independent Ethics Committee of each study centre. 
Women were randomised to receive 20 mg/day oral tamoxifen (Nolvadex-D; Astra-Zeneca) plus either 2.5 mg/ 
day oral tibolone (Livial; NV Organon) or matching placebo. Medication was started within three days of the 
baseline assessment (which was performed within 12 weeks of breast surgery) and was continued for 12 months. 
Compliance was checked by means of a daily diary and inquiry by the investigator. The automated random 
assignment of subject numbers to treatment groups was made by the Clinical Supply Management at Organon, 
using the Almedica Drug Labeling System (ADLS); the medication was then coded and labelled at Organon and 
dispensed by the investigator. Randomisation was done in blocks of four. Tibolone and placebo tablets were 
identical in shape, appearance and packaging. Assessments were performed at screening, baseline, three-monthly 
intervals during treatment and on discontinuation from the study. 
The women were screened with a medical, gynaecological and drug history, physical examination, 
gynaecological examination and cervical cytology, endometrial biopsy and routine laboratory analyses. 
Information on mammography results, site of breast malignancy, breast status after surgery, nodal status of the 
tumour, ratio of nodes containing metastases and oestrogen and progestogen receptor status of the malignancy 
were documented at baseline. 
The primary efficacy parameters were the frequency and severity of hot flushes at three months. This was 
documented by the patient using a seven-day diary card between the screening and baseline assessments and 
during the first three months of treatment. The severity of hot flushes was rated as mild (sensation of heat 
without perspiration), moderate (sensation of heat with sweating but able to continue activity) or severe 
(sensation of heat with sweating and unable to continue activity). These parameters are in accordance with the 
Food and Drug Administration guidance and have been used previously.14 In order to determine the average 
daily severity of hot flushes, a weighted average score was calculated for each patient: [(Number of mild hot 
flushes x 1) + (Number of moderate hot flushes x 2) + (Number of severe hot flushes x 3)]/Total number of hot 
flushes. 
Climacteric symptoms (hot flushes, sweats, palpitations, joint pain, vaginal dryness and incontinence) were also 
recorded on a checklist, adapted from the Landgren scale, ' at baseline and each visit. This checklist was 
completed by the investigator and reflected the patient's symptom recall over the previous week. Intensity was 
classified as: none (no symptoms), mild (not interfering with daily activities or sleep), moderate (interfering with 
daily activities or sleep, but these activities could be continued), severe (interfering with daily activities or sleep 
and stopping them for up to 5 minutes) or very severe (interfering with daily activities or sleep and stopping 
them for more than 5 minutes). 
Secondary efficacy parameters included interference of hot flushes and sweats with everyday life (none, mild, 
moderate, severe or very severe) and the intensity of palpitations, joint pain, vaginal dryness (none, mild, 
moderate, severe or very severe), all of which were assessed using a validated questionnaire.15, 16
Vital signs and routine laboratory parameters were measured before baseline and at each visit, together with a 
clinical examination of the breasts. A gynaecological examination and an endometrial biopsy were performed 
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after 6 and 12 months and a physical examination and mammography after 12 months. A monthly diary card was 
used to document the incidence of bleeding/spotting throughout the study. Adverse events were recorded 
throughout the study. A serious adverse event was defined as any event that was fatal or life-threatening, 
permanently disabling or required inpatient hospitalisation. 
The primary safety parameters were the incidence of vaginal bleeding/spotting and endometrial histology. 
Endometrial biopsies were classified as normal (no tissue obtained, tissue insufficient, atrophic/inactive, 
secretory, menstrual type or proliferative endometrium); abnormal (hyperplastic endometrium, carcinoma or 
other); or polyps. Secondary safety parameters comprised the serum lipid/ lipoprotein profile and the recurrence 
of breast cancer. 
The rationale for the sample size was based on data showing that after three months of tamoxifen treatment, up 
to 65% of the subjects experienced frequent and severe hot flushes.17 Assumptions were made concerning the 
expected proportions under combined tamoxifen and tibolone and the required number of subjects was calculated 
using a χ2 test. The working hypothesis was that, under combined tamoxifen and tibolone, this proportion would 
be a maximum of 30%, thus leading to an effective sample size of 32 per group. A difference between groups of 
about 0.7 times the standard deviation could be detected in the number of hot flushes (α = 0.05 two-tailed, 1 - β = 
0.80 power). 
Data were analysed on an intention-to-treat basis. Group comparisons were carried out using χ2 or Fisher's exact 
tests for dichotomous variables and non-parametric analysis for continuous variables. Data are presented as mean 
(standard deviation). 




A total of 75 women were screened between July 1996 and July 2000, of whom 70 were randomised to 
treatment, 35 in each group. All tibolone-treated patients completed the study, while three women in the placebo 
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group withdrew prematurely [one due to an adverse event (aggravation of Parkinson's disease) and two who 
were unwilling/unable to co-operate further] (Fig. 1). The baseline characteristics were similar in both groups 
(Table 1). 
The total exposure in the tibolone group was 35.1 woman years and in the placebo group 32.9 woman years. 
Dosing compliance was very high for both tibolone (99.5%) and placebo (97.8%). Almost 100% compliance was 
also seen with tamoxifen. 
Baseline data for the daily number of hot flushes were incomplete or missing for 16 women (tibolone, n = 7; 
placebo, n = 9). As hot flushes were not an entry requirement for the study, baseline data on severity were not 
available for a considerable number of women (tibolone, n = 19; placebo, n = 23). More women in the tibolone 
(78.6%) than in the placebo group (50%) experienced hot flushes at baseline. The changes in number and 
severity of hot flushes recorded on diary cards are shown in Table 2. 
Using the Landgren scale, more women in the tibolone group than in the placebo group experienced hot flushes 
(72.7% vs 39.4%) and sweats (54.5% vs 36.4%) at baseline. Thirty-three women in the tibolone group and 31 in 
the placebo group had baseline and final visit data available. There was a decrease of approximately 30% in the 
occurrence of hot flushes and sweats with tibolone and an increase of approximately 30% with placebo after 12 
months of treatment. The mean change from baseline in the number of hot flushes was -0.6 with tibolone and + 
1.1 with placebo (P = 0.022); the corresponding changes in the number of sweats were -0.6 and 1.2, respectively 
(P = 0.22). The mean change in intensity with tibolone and placebo was -0.2 and +0.2, respectively (P = 0.09), 
for hot flushes and -0.2 and +0.3, respectively (P = 0.15), for sweats. 
The percentage of women in whom hot flushes and sweats did not interfere with everyday life increased from 
52% to 74% at 12 months in the tibolone group (P = 0.071) and from 64% to 70% in the placebo group  
(P = 0.48). Only minor changes were seen in the other climacteric symptoms, with no significant differences 
between the groups (data not shown). 
Biopsies were obtained from 35 women in the tibolone group and 32 in the placebo group at baseline and 33 in 
the tibolone group and 30 women in the placebo groups at 12 months. All biopsies were defined as normal. The 
results were mainly 'atrophic/inactive' in the tibolone group (one woman with secretory endometrium) and 'tissue 
insufficient' in the placebo group (one women with proliferative endometrium). An increase in endometrial 
thickness occurred in both groups during the first three months. Although the increase was more marked in the 
tibolone group at the start of the study, the endometrial thickness was similar in both groups from month nine 
onwards (data not shown). Three women (one in the tibolone group and two in the placebo group) underwent 
hysteroscopy and curettage but no evidence of malignancy was detected. 
Vaginal bleeding or spotting occurred in 10 women (28.6%) receiving tibolone and 7 women (20.6%) receiving 
placebo (P = 0.44). The mean duration of bleeding was 3.9 (3.8) days with tibolone and 2.7 (2.6) with placebo 
(not significant). There were no differences in the number of episodes or timing of bleeding between the groups. 
Table 1: Baseline characteristics of study patients. Values are presented as mean [SD] or n (%). 
 Tibolone 
(n = 35) 
Placebo 
(n = 35) 
Age (years) 58 [6.1] 59 [5.5] 
Body weight (kg) 65 [9]a 68 [11] 
Height (cm) 162 [6.8] 163 [6.5] 
Body mass index (kg/m2) 24.8 [3.2]a 25.4 [3.7] 
Time since menopause (months) 105 [75]a 109 [61]a
Median tumour size (mm) 13.5a 14.0 
Patients with   
Positive axillary nodes 6 (17) 7 (20) 
Positive oestrogen receptor 28 (85)b 34 (97) 
Positive progestogen receptor 22 (68)c 23 (68)a
an = 34.  
bn = 33.  
cn = 32. 
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Table 2: Daily number and severity of hot flushes at baseline and after three months of treatment, and change 
from baseline (diary cards). Values are presented as mean [SD]. 
 Tibolone Placebo P 
No. of hot flushes    
Baseline 2.0 [2.1]a 2.2 [3.3]b  
Last week 2.1 [2.1]c 2.9 [3.2]d 0.66 
Change from baseline -0.1 [1.9]b 0.9 [3.4]b 0.22 
Severity of hot flushes*    
Baseline 1.6 [0.6]e 1.6 [0.5]f  
Last week 1.4 [0.3]e 1.7 [0.6]g 0.11 
Change from baseline -0.4 [0.7]h 0.2 [0.4]h 0.03 
an = 28. 
bn = 26.  
cn = 30.  
dn = 32. 
en = 16.  
fn = 12. 
gn = 17.  
hn = 8. 
* Weighted average score. 
Table 3: Baseline values for lipids and lipoproteins parameters and percentage change from baseline at 12 
months. Values are presented as mean [SD]. 
 Tibolone Placebo P 
Triglycerides (mmol/L)    
Baseline 1.7 [l.l]a 1.7 [0.8]b  
% Change at 12 months -23 [27]c 1.4 [36]d 0.005 
Lipoprotein(a) (U/L)    
Baseline 292 [358]c 254 [342]c  
% Change at 12 months -14 [83]c 7 [120]e 0.46 
LDL (mmol/L)    
Baseline 3.8 [0.9]a 4.1 [1.0]b  
% Change at 12 months 4.8 [31]c -15 [14]d 0.0029 
HDL (mmol/L)    
Baseline 1.4 [0.4]a 1.3 [0.3]b  
% Change at 12 months -12 [22]c 19 [26]d <0.001 
Cholesterol total (mmol/L)    
Baseline 5.9 [1.0]a 6.1 [1.2]b  
% Change at 12 months -4.8 [22]c -6.2 [15]d 0.78 
an = 30.  
bn = 31. 
cn = 29.  
dn = 27.  
en = 25. 
Table 4: Adverse events. Values are presented as n (%). 
 Tibolone Placebo 
Erythema 10 (29) 10 (29) 
Skin disorder 1 (2.9) 4 (11) 
Joint pain 6 (17) 1 (2.9) 
Weight increase 4 (11) 7 (20) 
Vaginitis 6 (17) 2 (5.7) 
Back pain 2 (5.7) 5 (14) 
Influenza-like symptoms 1 (2.9) 4 (11) 
Oedema 4 (11) 3 (8.6) 
In the tibolone-treated patients, a significant decrease in triglycerides (-23% vs 1.4%) and HDL (-12% vs 19%) 
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could be observed after 12 months of treatment (see Table 3). 
None of the women in either group experienced a recurrence of breast cancer. Mammography results and breast 
examinations did not reveal any clinically significant findings. Adverse events were reported by 25 women 
(71%) in the tibolone group and 29 (83%) in the placebo group (Table 4). 
DISCUSSION 
In this study, we have demonstrated that tibolone prevented the increase in the occurrence, severity and intensity 
of hot flushes and sweats associated with tamoxifen treatment following surgical treatment for breast cancer. 
There was also a trend for tibolone to reduce the impact of hot flushes and sweats on normal daily life. Tibolone 
has been used effectively for the management of climacteric symptoms in a previous small study involving 15 
postmenopausal women with breast cancer who had undergone surgery and radiotherapy. As in the current 
study, none of the patients suffered a recurrence of breast cancer and eight were still being treated with tibolone 
one year after the end of the study. 
Clinical evidence indicates that tibolone is associated with a lower incidence of breast tenderness than 
conventional oestrogen replacement therapy19-22 and that it does not appear to change breast density.11,22-26 For 
example, in a six-month, double-blind, placebo-controlled study in 166 healthy postmenopausal women, 46% of 
those taking continuous combined oestrogen replacement therapy had an increase in breast density (Wolfe 
classification) compared with 2% taking tibolone and 0% receiving placebo.22 Increased density can impair 
interpretation of mammograms and thus reduce the sensitivity of screening programmes to detect breast cancer.27 
These observations support preclinical research indicating that tibolone does not exert an oestrogenic effect on 
the breast.10,12,13 Nevertheless, the clinical significance of these findings is currently unclear and the relationship 
between tibolone and breast cancer will require further evaluation. 
The recent Million Women Study, which recruited over 1 million women aged 50-64 years, reported that all 
types of hormone therapy were associated with an increased risk of breast cancer, this was substantially greater 
for oestrogen and progestogen therapy than for tibolone and oestrogen alone.28 The proportion of tibolone users 
was small (6%) and it is unclear whether these women carried risk factors other than those controlled for in the 
analyses.29-31 In contrast to the Million Women Study, a large case-control study in the UK General Physicians 
Database, with a similar number of breast cancer cases, did not reveal an increased risk for breast cancer in 
women treated with tibolone.32
The reported increased risk of breast cancer with oestrogen containing hormone therapy may be partially due to 
accelerated tumour growth, a factor which is clearly not applicable to women who have had surgery. However, 
the growth of micro-metastases may be enhanced leading to an increased recurrence rate. Two recent 
(prematurely stopped) randomised trials provided conflicting information. The HABITS Trial reported an 
increased risk for new breast cancer events which was not confirmed in the Stockholm Trial.4 The effect of 
tibolone on the breast recurrence rate in women with a history of breast cancer is currently being assessed in a 
large double-blind, randomised, placebo-controlled, five-year clinical trial (LIBERATE). 
Endometrial safety is an important issue in women receiving tamoxifen treatment.9 As expected,33 there was an 
initial increase in endometrial thickness in both groups in our study. Nevertheless, the endometrial biopsies were 
all normal. The endometrial safety of tibolone has been previously established,5 and the current findings indicate 
that this profile is maintained in women receiving tamoxifen treatment. The effects of tibolone on serum lipid 
and lipoprotein levels were in line with those from previous reports and therefore appear to be unaffected by 
concomitant tamoxifen treatment. 
At present, there are no approved effective compounds to treat postmenopausal women with a history of breast 
cancer who are suffering from climacteric symptoms. The findings from this pilot study are promising, but only 
a large, long term clinical trial can provide confirmatory data regarding the effects of tibolone on recurrence in 
breast cancer patients. 
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